MedTrace Logo

Medication Abortion Via Pharmacy Dispensing

NCT03320057 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2021-07-12

Study results available
· View outcomes & findings →

Summary

This mixed-methods study follows a prospective cohort of patients receiving Mifeprex ® (mifepristone) for medication abortion dispensed by pharmacists after undergoing standard clinical evaluation. Women participating in this study will obtain mifepristone and misoprostol from the pharmacy instead of in the clinic. To assess feasibility, acceptability, and effectiveness of pharmacy dispensing of mifepristone, the study will survey patients, evaluate their clinical outcomes from electronic health records, and survey and interview pharmacists at study sites.

Conditions

  • Pregnancy Related
  • Abortion Early

Interventions

DRUG

Mifepristone

Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit

OTHER

Training on mifepristone dispensing

Pharmacists were offered a training on medication abortion and mifepristone dispensing

Sponsors & Collaborators

  • University of California, San Diego

    collaborator OTHER

  • University of California, Davis

    collaborator OTHER

  • University of Washington

    collaborator OTHER

  • Kaiser Permanente

    collaborator OTHER

  • Planned Parenthood of the Great Northwest and Hawaiian Islands

    collaborator OTHER

  • Daniel Grossman

    lead OTHER

Principal Investigators

  • Daniel Grossman, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2020-07-04
Completion
2020-07-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03320057 on ClinicalTrials.gov